Eloxx Pharmaceuticals develops drug candidates for rare genetic kidney and dermatologic diseases. ELOX reports earnings on Tue, Nov 10, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Guggenheim | Target lowered | Buy | |
| Sep 18 | Leerink Partners | Initiated | Buy | |
| Aug 20 | LUCID CAPITAL MARKETS | Initiated | Buy | |
| Jul 22 | LifeSci Capital | Initiated | Buy | |
| Jul 20 | Guggenheim | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in ELOX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELOX is in one of them and how their past ELOX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ELOX in an article yet. Here's the latest on the wider market.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a drug development company based in Arlington, Massachusetts. It is developing product candidates for rare genetic kidney and dermatologic diseases, with an approach that targets processes such as fibrosis, inflammation and proteinuria. Its candidates are still in development. If approved, they would be prescribed to patients by physicians.
- Headquarters
- Arlington, MA